Makers Of Pradaxa Issue Voluntary Recall Due To Safety Concerns

November 20, 2012

Drug manufacturer, Boehringer Ingelheim Pharmaceuticals, Inc., recently issued a voluntary recall on one of its medications due to a packaging defect that could affect the quality of the medication and could lead to a drug injury. According to Packaging World, only one lot of the medication was affected.

Reports indicate that lot 201900 of the medication, Pradaxa®, may have been damaged allowing moisture in. This can cause the active ingredient in the medication to degrade and patients to not receive full doses. Considering the medication is used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), not receiving a full dose of medication could cause patients to suffer serious adverse health events.

Patients who may be in possession of an affected bottle of Pradaxa have been instructed to continue to take their medications as directed until a replacement bottle can be procured. Pharmacists who received part of the affected lot have been instructed to contact patients who may have received the defective products as well.

The Drug Injury Lawyers with Ferrer, Poirot & Wansbrough understand drug distributors and manufacturers have a responsibility to ensure the safety of those who use their product and failure to do so could be considered negligence. This is why the firm would encourage anyone who has been harmed by taking a medication prescribed to you by a doctor to contact an attorney immediately.